Literature DB >> 30603638

Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? -a single-center retrospective study.

Zi-Feng Yang1, De-Qing Wu1, Jun-Jiang Wang1, Xing-Yu Feng1, Jia-Bin Zheng1, Wei-Xian Hu1, Yong Li1.   

Abstract

BACKGROUND: The surgical approach (transthoracic or transabdominal) for patients with Siewert type II adenocarcinoma of the esophagogastric junction (AEG) still remains controversial.
METHODS: Data of patients with Siewert type II AEG were collected in the Guangdong General Hospital from 2004 to 2014 and we compared their clinicopathological outcome and prognosis in regard to the transthoracic (TT) and transabdominal (TA) approach.
RESULTS: A total of 158 patients with Siewert type II AEG were analyzed and our results demonstrated that their overall medium survival was 52 months. Also, their 5-year overall survival rate was 39.1%, which was comparable between the TT and TA group (35.1% vs. 43.2%, P>0.05), while more lymph nodes were dissected in TA group (23.7±0.2 vs. 18.1±0.3, P<0.05), with less postoperative complications (14.3% vs. 28.4%, P<0.05) and shorten hospital stay (12±4 vs. 15±7 d, P<0.05).
CONCLUSIONS: For patients with Siewert type II AEG, the TA approach is more suitable to achieve an optimal extent of lymph node dissection, reduction in the incidence of complication, shorten hospital stay, and to promote the recovery.

Entities:  

Keywords:  Adenocarcinoma of the esophagogastric junction (AEG); Siewert type II; surgical approach

Year:  2018        PMID: 30603638      PMCID: PMC6312814          DOI: 10.21037/atm.2018.10.66

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  22 in total

Review 1.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

2.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.

Authors:  Mitsuru Sasako; Takeshi Sano; Seiichiro Yamamoto; Motonori Sairenji; Kuniyoshi Arai; Taira Kinoshita; Atsushi Nashimoto; Masahiro Hiratsuka
Journal:  Lancet Oncol       Date:  2006-08       Impact factor: 41.316

3.  Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG).

Authors:  Leila Sisic; Susanne Blank; Wilko Weichert; Dirk Jäger; Christoph Springfeld; Marcel Hochreiter; Markus Büchler; Katja Ott
Journal:  Langenbecks Arch Surg       Date:  2013-07-26       Impact factor: 3.445

4.  Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Kazuhito Tsuchida; Haruhiko Cho; Takashi Oshima; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Akira Tsuburaya
Journal:  Ann Surg Oncol       Date:  2012-12-09       Impact factor: 5.344

5.  Lymph node metastasis and lymphadenectomy of resectable adenocarcinoma of the esophagogastric junction.

Authors:  Xin-Zu Chen; Wei-Han Zhang; Jian-Kun Hu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

Review 6.  Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a meta-analysis.

Authors:  Ming-Tian Wei; Yuan-Chuan Zhang; Xiang-Bing Deng; Ting-Han Yang; Ya-Zhou He; Zi-Qiang Wang
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma.

Authors:  Hiroharu Yamashita; Hitoshi Katai; Shinji Morita; Makoto Saka; Hirokazu Taniguchi; Takeo Fukagawa
Journal:  Ann Surg       Date:  2011-08       Impact factor: 12.969

Review 8.  [The new TNM classification of tumors of the esophagogastric junction. Surgical consequences].

Authors:  C Schuhmacher; A Novotny; M Feith; H Friess
Journal:  Chirurg       Date:  2012-01       Impact factor: 0.955

9.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.

Authors:  Jikke M T Omloo; Sjoerd M Lagarde; Jan B F Hulscher; Johannes B Reitsma; Paul Fockens; Herman van Dekken; Fiebo J W Ten Kate; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

10.  The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients.

Authors:  Hironobu Goto; Masanori Tokunaga; Yuichiro Miki; Rie Makuuchi; Norihiko Sugisawa; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masahiro Niihara; Yasuhiro Tsubosa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2014-03-22       Impact factor: 7.370

View more
  2 in total

1.  Comparison of Efficacy Between Transabdominal and Transthoracic Surgical Approaches for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Systematic Review and Meta-Analysis.

Authors:  Zonglin Li; Huaiwu Jiang; Jin Chen; Yifan Jiang; Yi Liu; Linxia Xu
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

2.  Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients.

Authors:  Yao Chen; Xue Ke Zhao; Rui Hua Xu; Xin Song; Miao Miao Yang; Fu You Zhou; Ling Ling Lei; Zong Min Fan; Xue Na Han; She Gan Gao; Xian Zeng Wang; Zhi Cai Liu; Ai Li Li; Wen Jun Gao; Jing Feng Hu; Li Guo Zhang; Jin Chang Wei; Fu Lin Jiao; Kan Zhong; Wei Peng Wang; Liu Yu Li; Jia Jia Ji; Xue Min Li; Li Dong Wang
Journal:  World J Surg Oncol       Date:  2022-06-28       Impact factor: 3.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.